Using two donors, the fish genome was sequenced and assembled, quantified for repeats, and geneannotated with new and existing transcript sequence. Most of the process used standard practices and overall it appears well done. The genome and transcript assemblies are in GenBank. A new long-read technology was incorporated to extend the assembly scaffolds. The result was validated by gene content but no other means.
I found the title misleading. The Title implies that the manuscript is mostly about integrating long and short reads. The Abstract is also largely about Nanopore. With this setup, the manuscript is bound to disappoint: no comparison of Nanopore to other long-range linkage technologies, no titration analysis of benefit per unit coverage, no examination of whether the 2D reads helped more than the 1D reads, no comparison of Nanopore basecallers, no quantification of read accuracy, no analysis of whether the scaffold software performed correctly on data for which it was not designed, and most critically, no validation that the Nanopore extensions to scaffolds were correct. * The manuscript will read better if the Title and Abstract change to reflect what the manuscript is actually about. * The manuscript should address the unknown accuracy of the scaffold extensions. * The words "practical and effective" (Conclusion) are not defined or backed by analysis. * The scaffold growth should not be called "significant" without statistics. * For clarity, the word "contiguity" should be reserved for contig growth and not applied to scaffold growth. * The Nanopore read length N50 seems low but I don't know if there is anything to say about this.
I found the use of a second donor to be problematic and it only struck me on the second read. The second donor may have introduced sequence differences and structural variations relative to the first. Different sequencing technologies were applied to each donor and the longer Illumina reads from the second donor could have biased the assembly toward it. The assembly could contain falsely duplicated genes that are single-copy in both donors but different enough to assemble separately. On the other hand, there may have been too few second-donor reads to matter, but then why were they used? * The manuscript will be more helpful if this problem is addressed. Mention the dual donors in the Abstract. Elsewhere, explain why two donors were used. Quantify coverage per donor. Address whether the donors are the same gender. * Explore the possible effects of use of the second donor. Are any scaffolds formed from the reads of one donor only? * Explain the use of Platanus. It seems this assembler was chosen to overcome heterozygosity, but what did this assembler do especially for the heterozygosity? The observed heterozygosity (Figure 1 ) seems low, so perhaps the issue turned out less serious than anticipated. If so, was the use of Platanus risky in any way?
The Abstract, Introduction, and Conclusion claim this is the first genome and transcriptome of an Australian teleost. The Data Description claims that a lack of similar resources limits current understanding. These claims beg for a reference. Failing that, the authors could describe how they came to these conclusions. Or they could save it for Discussion. Or use the dreaded "to our knowledge." I would leave it out.
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